HMGB1-mediated autophagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation
Metrics: PDF 833 views | HTML 1509 views | ?
Hubin Yin1,2, Xiaoyu Yang1,2, Wen Gu1, Yan Liu1, Xinyuan Li1,2, Xiaolong Huang1, Xin Zhu1, Yong Tao1,2, Xin Gou1 and Weiyang He1
1Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
2Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Weiyang He, email: firstname.lastname@example.org
Xin Gou, email: email@example.com
Keywords: high-mobility group box 1, autophagy, chemoresistance, mitogen-activated protein kinase, bladder carcinoma
Received: November 04, 2016 Accepted: April 25, 2017 Published: May 11, 2017
High-mobility group box 1 (HMGB1) has been found to mediate autophagy during chemotherapy in several cancers. However, whether HMGB1plays a role in autophagy and chemoresistance in bladder cancer is elusive. In this report, HMGB1 expression was found to be increased in 30 primary bladder cancer tissue specimens compared to their matched adjacent non-tumor tissues. While gemcitabine induced apoptotic cell death, it also induced HMGB1 expression and autophagy in bladder cancer T24 and BIU-87 cells. Suppressing HMGB1 expression with siRNA strongly potentiated gemcitabine-induced apoptosis. HMGB1 siRNA or autophagy inhibitors suppressed gemcitabine-induced autophagy. Further, gemcitabine activated c-Jun N-terminal kinase (JNK) and extracellular regulated protein kinase (ERK) and Bcl-2 phosphorylation, and blocking ERK and JNK inhibited autophagy and increased apoptosis in gemcitabine-treated cells. Interestingly, suppressing HMGB1 expression attenuated gemcitabine-induced ERK and JNK activation and Bcl-2 phosphorylation. Thus, our results suggest that while gemcitabine kills bladder cancer cells through apoptosis, a cytoprotective autophagy is also induced involving HMGB1-mediated JNK and ERK to counteract the cytotoxicity of gemcitabine, and intervention targeting this pathway may improve the anticancer efficacy of gemcitabine against bladder cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.